Skip to content
Back to SLDB

Solid Biosciences Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
28
Purchases
0
Sales
28
Purchase value
$0.00
Sale value
$2.68M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Gabriel BrooksChief Medical Officer
4Rule 10b5-1 plan disclosed
Filed Oct 20, 2026Period of report Oct 18, 20260001193125-26-426668
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 19, 2026
Common StockF34,374$5.62$24.58K97,241Direct
Filing footnotes · 4
  1. F1Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
  2. F2Includes 2,399 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 29, 2026.
  3. F3This sale was made to cover withholding taxes following the vesting of previously granted RSUs pursuant to a durable automatic sale instruction letter adopted by Dr. Brooks on August 15, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Brooks.
  4. F4The RSUs were granted on October 18, 2023 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.
Open on SEC EDGAR
Alexander CumboDirector · President and CEO
4Rule 10b5-1 plan disclosed
Filed Feb 18, 2026Period of report Feb 13, 20260001193125-26-057878
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 18, 2026
Common StockF2F316,644$5.8233$96.92K235,405Direct
Filing footnotes · 4
  1. F1Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").
  2. F2This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Mr. Cumbo on August 18, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Cumbo.
  3. F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.23 to $6.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.
  4. F4The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.
Open on SEC EDGAR
Jessie HanrahanChief Regulatory Officer
4Rule 10b5-1 plan disclosed
Filed Feb 18, 2026Period of report Feb 13, 20260001193125-26-057872
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 18, 2026
Common StockF2F34,134$5.8233$24.07K74,318Direct
Filing footnotes · 4
  1. F1Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").
  2. F2This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Dr. Hanrahan on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Hanrahan.
  3. F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.23 to $6.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.
  4. F4The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.
Open on SEC EDGAR
Ilan GanotDirector
4Rule 10b5-1 plan disclosed
Filed Feb 18, 2026Period of report Feb 13, 20260001193125-26-057868
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 18, 2026
Common StockF3F42,658$5.8233$15.48K27,474IndirectWife
Filing footnotes · 6
  1. F1Restricted stock units convert into common stock on a one-for-one basis.
  2. F2Represents 95,255 shares held by Mr. Ganot as an individual, and 4,042 shares held by Mr. Ganot and Annie Ganot as joint tenants with right of survivorship.
  3. F3This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units pursuant to a durable automatic sales instruction letter adopted by Ms. Ganot on September 25, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Ms. Ganot.
  4. F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.23 to $6.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.
  5. F5Represents 19,394 shares held by Adam Ganot and Annie Ganot, and their successors, as the trustees for the Ilan Ganot 2017 Irrevocable Trust dated March 3, 2017.
  6. F6On February 13, 2024 (the "Grant Date") Ms. Ganot was granted 19,444 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date.
Open on SEC EDGAR
Paul HerzichChief Technology Officer
4Rule 10b5-1 plan disclosed
Filed Feb 18, 2026Period of report Feb 13, 20260001193125-26-057865
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 18, 2026
Common StockF2F33,616$5.8233$21.06K72,638Direct
Filing footnotes · 4
  1. F1Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").
  2. F2This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Mr. Herzich on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Herzich.
  3. F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.23 to $6.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.
  4. F4The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.
Open on SEC EDGAR
David T HowtonChief Operating Officer
4Rule 10b5-1 plan disclosed
Filed Feb 18, 2026Period of report Feb 13, 20260001193125-26-057863
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 18, 2026
Common StockF2F37,469$5.8233$43.49K105,077Direct
Filing footnotes · 4
  1. F1Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").
  2. F2This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Mr. Howton on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Howton.
  3. F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.23 to $6.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.
  4. F4The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.
Open on SEC EDGAR
Gabriel BrooksChief Medical Officer
4Rule 10b5-1 plan disclosed
Filed Feb 18, 2026Period of report Feb 13, 20260001193125-26-057859
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 18, 2026
Common StockF2F30$5.8233$0.0089,466Direct
Filing footnotes · 4
  1. F1Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").
  2. F2This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Dr. Brooks on August 15, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Brooks.
  3. F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.23 to $6.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.
  4. F4The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.
Open on SEC EDGAR
Kevin TanCFO & Treasurer
4Rule 10b5-1 plan disclosed
Filed Feb 18, 2026Period of report Feb 13, 20260001193125-26-057855
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 18, 2026
Common StockF2F35,404$5.8233$31.47K99,422Direct
Filing footnotes · 4
  1. F1Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").
  2. F2This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Mr. Tan on August 15, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Tan.
  3. F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.23 to $6.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.
  4. F4The restricted stock units were granted on February 13, 2025 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.
Open on SEC EDGAR
David T HowtonChief Operating Officer
4Rule 10b5-1 plan disclosed
Filed Feb 6, 2026Period of report Feb 4, 20260001193125-26-041523
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 4, 2026
Common StockF1F218,894$6.4419$121.71K97,859Direct
Filing footnotes · 2
  1. F1This sale was made to cover withholding taxes following the vesting of previously granted restricted stock units pursuant to a durable automatic sale instruction letter adopted by Mr. Howton on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Howton.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.28 to $6.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.
Open on SEC EDGAR
Alexander CumboDirector · President and CEO
4Rule 10b5-1 plan disclosed
Filed Feb 6, 2026Period of report Feb 4, 20260001193125-26-041519
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 4, 2026
Common StockF1F248,913$6.4419$315.09K222,018Direct
Filing footnotes · 2
  1. F1This sale was made to cover withholding taxes following the vesting of previously granted restricted stock units pursuant to a durable automatic sale instruction letter adopted by Mr. Cumbo on August 18, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Cumbo.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.28 to $6.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.
Open on SEC EDGAR
Ilan GanotDirector
4Rule 10b5-1 plan disclosed
Filed Feb 6, 2026Period of report Feb 4, 20260001193125-26-041516
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 4, 2026
Common StockF1F27,205$6.4419$46.41K25,271IndirectWife
Filing footnotes · 4
  1. F1This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units pursuant to a durable automatic sales instruction letter adopted by Ms. Ganot on September 25, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Ms. Ganot.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.28 to $6.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.
  3. F3Represents 95,255 shares held by Mr. Ganot as an individual, and 4,042 shares held by Mr. Ganot and Annie Ganot as joint tenants with right of survivorship.
  4. F4Represents 19,394 shares held by Adam Ganot and Annie Ganot, and their successors, as the trustees for the Ilan Ganot 2017 Irrevocable Trust dated March 3, 2017.
Open on SEC EDGAR
Kevin TanCFO & Treasurer
4Rule 10b5-1 plan disclosed
Filed Feb 6, 2026Period of report Feb 4, 20260001193125-26-041514
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 4, 2026
Common StockF1F214,783$6.4419$95.23K94,201Direct
Filing footnotes · 2
  1. F1This sale was made to cover withholding taxes following the vesting of previously granted restricted stock units pursuant to a durable automatic sale instruction letter adopted by Mr. Tan on August 15, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Tan.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.28 to $6.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.
Open on SEC EDGAR
Gabriel BrooksChief Medical Officer
4Rule 10b5-1 plan disclosed
Filed Feb 6, 2026Period of report Feb 4, 20260001193125-26-041511
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 4, 2026
Common StockF1F212,616$6.4419$81.27K84,092Direct
Filing footnotes · 2
  1. F1This sale was made to cover withholding taxes following the vesting of previously granted restricted stock units pursuant to a durable automatic sale instruction letter adopted by Dr. Brooks on August 15, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Brooks.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.28 to $6.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.
Open on SEC EDGAR
Jessie HanrahanChief Regulatory Officer
4Rule 10b5-1 plan disclosed
Filed Feb 6, 2026Period of report Feb 4, 20260001193125-26-041507
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 4, 2026
Common StockF1F212,348$6.4419$79.54K70,327Direct
Filing footnotes · 2
  1. F1This sale was made to cover withholding taxes following the vesting of previously granted restricted stock units pursuant to a durable automatic sale instruction letter adopted by Dr. Hanrahan on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Hanrahan.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.28 to $6.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.
Open on SEC EDGAR
Paul HerzichChief Technology Officer
4Rule 10b5-1 plan disclosed
Filed Feb 6, 2026Period of report Feb 4, 20260001193125-26-041506
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 4, 2026
Common StockF1F210,905$6.4419$70.25K69,067Direct
Filing footnotes · 2
  1. F1This sale was made to cover withholding taxes following the vesting of previously granted restricted stock units pursuant to a durable automatic sale instruction letter adopted by Mr. Herzich on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Herzich.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.28 to $6.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.
Open on SEC EDGAR
Kevin TanCFO & Treasurer
4Rule 10b5-1 plan disclosed
Filed Feb 2, 2026Period of report Jan 29, 20260001193125-26-034089
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 2, 2026
Common StockF3F426,837$6.4369$172.75K108,984Direct
Filing footnotes · 8
  1. F1Each performance stock unit ("PSUs") converts to common stock on a one-for-one basis.
  2. F2Each restricted stock unit ("RSUs") converts to common stock on a one-for-one basis.
  3. F3This sale was made to cover withholding taxes following the vesting of previously granted PSUs pursuant to a durable automatic sale instruction letter adopted by Mr. Tan on August 15, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Tan.
  4. F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.295 to $6.580, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.
  5. F5The PSUs were granted on June 11, 2024 and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"), subject to the grantee's continued service with the Company (the "Approval Conditions"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the first Performance Milestone was determined to be met on January 29, 2026 (the "2026 Grant Date") resulting in the vesting of the PSUs as to 25% of the underlying shares.
  6. F6This option was granted on the 2026 Grant Date and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the 2026 Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary.
  7. F7The RSUs were granted on the 2026 Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the 2026 Grant Date until the fourth such anniversary.
  8. F8On January 31, 2025 (the "2025 Grant Date"), the reporting person was granted 132,300 RSUs, with 25% of the original number of shares vesting on each anniversary of the 2025 Grant Date until the fourth such anniversary.
Open on SEC EDGAR
Alexander CumboDirector · President and CEO
4Rule 10b5-1 plan disclosed
Filed Feb 2, 2026Period of report Jan 29, 20260001193125-26-034087
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 2, 2026
Common StockF3F480,258$6.4369$516.61K270,931Direct
Filing footnotes · 8
  1. F1Each performance stock unit ("PSUs") converts to common stock on a one-for-one basis.
  2. F2Each restricted stock unit ("RSUs") converts to common stock on a one-for-one basis.
  3. F3This sale was made to cover withholding taxes following the vesting of previously granted PSUs pursuant to a durable automatic sale instruction letter adopted by Mr. Cumbo on August 18, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Cumbo.
  4. F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.295 to $6.580, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.
  5. F5The PSUs were granted on June 11, 2024 and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"), subject to the grantee's continued service with the Company (the "Approval Conditions"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the first Performance Milestone was determined to be met on January 29, 2026 (the "2026 Grant Date") resulting in the vesting of the PSUs as to 25% of the underlying shares.
  6. F6This option was granted on the 2026 Grant Date and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the 2026 Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary.
  7. F7The RSUs were granted on the 2026 Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the 2026 Grant Date until the fourth such anniversary.
  8. F8On January 31, 2025 (the "2025 Grant Date"), the reporting person was granted 401,600 RSUs, with 25% of the original number of shares vesting on each anniversary of the 2025 Grant Date until the fourth such anniversary.
Open on SEC EDGAR
Jessie HanrahanChief Regulatory Officer
4Rule 10b5-1 plan disclosed
Filed Feb 2, 2026Period of report Jan 29, 20260001193125-26-034085
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 2, 2026
Common StockF3F426,535$6.4369$170.80K82,675Direct
Filing footnotes · 8
  1. F1Each performance stock unit ("PSUs") converts to common stock on a one-for-one basis.
  2. F2Each restricted stock unit ("RSUs") converts to common stock on a one-for-one basis.
  3. F3This sale was made to cover withholding taxes following the vesting of previously granted PSUs pursuant to a durable automatic sale instruction letter adopted by Dr. Hanrahan on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Hanrahan.
  4. F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.295 to $6.580, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.
  5. F5The PSUs were granted on June 11, 2024 and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"), subject to the grantee's continued service with the Company (the "Approval Conditions"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the first Performance Milestone was determined to be met on January 29, 2026 (the "2026 Grant Date") resulting in the vesting of the PSUs as to 25% of the underlying shares.
  6. F6This option was granted on the 2026 Grant Date and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the 2026 Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary.
  7. F7The RSUs were granted on the 2026 Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the 2026 Grant Date until the fourth such anniversary.
  8. F8On January 31, 2025 (the "2025 Grant Date"), the reporting person was granted 110,500 RSUs, with 25% of the original number of shares vesting on each anniversary of the 2025 Grant Date until the fourth such anniversary.
Open on SEC EDGAR
Gabriel BrooksChief Medical Officer
4Rule 10b5-1 plan disclosed
Filed Feb 2, 2026Period of report Jan 29, 20260001193125-26-034083
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 2, 2026
Common StockF4F528,335$6.4369$182.39K96,708Direct
Filing footnotes · 9
  1. F1Each performance stock unit ("PSUs") converts to common stock on a one-for-one basis (the "PSUs").
  2. F2Includes 4,152 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on November 28, 2025.
  3. F3Each restricted stock unit ("RSUs") converts to common stock on a one-for-one basis.
  4. F4This sale was made to cover withholding taxes following the vesting of previously granted PSUs pursuant to a durable automatic sale instruction letter adopted by Dr. Brooks on August 15, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Brooks.
  5. F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.295 to $6.580, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.
  6. F6The PSUs were granted on June 11, 2024 and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"), subject to the grantee's continued service with the Company (the "Approval Conditions"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the first Performance Milestone was determined to be met on January 29, 2026 (the "2026 Grant Date") resulting in the vesting of the PSUs as to 25% of the underlying shares.
  7. F7This option was granted on the 2026 Grant Date and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the 2026 Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary.
  8. F8The RSUs were granted on the 2026 Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the 2026 Grant Date until the fourth such anniversary.
  9. F9On January 31, 2025 (the "2025 Grant Date"), the reporting person was granted 112,900 RSUs, with 25% of the original number of shares vesting on each anniversary of the 2025 Grant Date until the fourth such anniversary.
Open on SEC EDGAR
David T HowtonChief Operating Officer
4Rule 10b5-1 plan disclosed
Filed Feb 2, 2026Period of report Jan 29, 20260001193125-26-034080
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 2, 2026
Common StockF3F437,771$6.4369$243.13K116,753Direct
Filing footnotes · 8
  1. F1Each performance stock unit ("PSUs") converts to common stock on a one-for-one basis.
  2. F2Each restricted stock unit ("RSUs") converts to common stock on a one-for-one basis.
  3. F3This sale was made to cover withholding taxes following the vesting of previously granted PSUs pursuant to a durable automatic sale instruction letter adopted by Mr. Howton on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Howton.
  4. F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.295 to $6.580, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.
  5. F5The PSUs were granted on June 11, 2024 and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"), subject to the grantee's continued service with the Company (the "Approval Conditions"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the first Performance Milestone was determined to be met on January 29, 2026 (the "2026 Grant Date") resulting in the vesting of the PSUs as to 25% of the underlying shares.
  6. F6This option was granted on the 2026 Grant Date and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the 2026 Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary.
  7. F7The RSUs were granted on the 2026 Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the 2026 Grant Date until the fourth such anniversary.
  8. F8On January 31, 2025 (the "2025 Grant Date"), the reporting person was granted 169,100 RSUs, with 25% of the original number of shares vesting on each anniversary of the 2025 Grant Date until the fourth such anniversary.
Open on SEC EDGAR
Paul HerzichChief Technology Officer
4Rule 10b5-1 plan disclosed
Filed Feb 2, 2026Period of report Jan 29, 20260001193125-26-034076
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 2, 2026
Common StockF3F426,250$6.4369$168.97K79,972Direct
Filing footnotes · 8
  1. F1Each performance stock unit ("PSUs") converts to common stock on a one-for-one basis.
  2. F2Each restricted stock unit ("RSUs") converts to common stock on a one-for-one basis.
  3. F3This sale was made to cover withholding taxes following the vesting of previously granted PSUs pursuant to a durable automatic sale instruction letter adopted by Mr. Herzich on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Herzich.
  4. F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.295 to $6.580, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.
  5. F5The PSUs were granted on June 11, 2024 and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"), subject to the grantee's continued service with the Company (the "Approval Conditions"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the first Performance Milestone was determined to be met on January 29, 2026 (the "2026 Grant Date") resulting in the vesting of the PSUs as to 25% of the underlying shares.
  6. F6This option was granted on the 2026 Grant Date and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the 2026 Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary.
  7. F7The RSUs were granted on the 2026 Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the 2026 Grant Date until the fourth such anniversary.
  8. F8On January 31, 2025 (the "2025 Grant Date"), the reporting person was granted 98,700 RSUs, with 25% of the original number of shares vesting on each anniversary of the 2025 Grant Date until the fourth such anniversary.
Open on SEC EDGAR
Ilan GanotDirector
4Rule 10b5-1 plan disclosed
Filed Jan 30, 2026Period of report Jan 27, 20260001193125-26-031765
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 28, 2026
Common StockF2191$6.59$1.26K17,476IndirectWife
Filing footnotes · 6
  1. F1Restricted stock units convert into common stock on a one-for-one basis.
  2. F2This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units pursuant to a durable automatic sales instruction letter adopted by Ms. Ganot on September 25, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Ms. Ganot.
  3. F3Represents 95,255 shares held by Mr. Ganot as an individual, and 4,042 shares held by Mr. Ganot and Annie Ganot as joint tenants with right of survivorship.
  4. F4Represents 19,394 shares held by Adam Ganot and Annie Ganot, and their successors, as the trustees for the Ilan Ganot 2017 Irrevocable Trust dated March 3, 2017.
  5. F5On January 27, 2022 (the "Grant Date") Ms. Ganot was granted 1,553 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date.
  6. F6On the Grant Date, the reporting person was granted 15,533 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date.
Open on SEC EDGAR
Kevin TanCFO & Treasurer
4Rule 10b5-1 plan disclosed
Filed Jan 13, 2026Period of report Jan 9, 20260001193125-26-011873
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 13, 2026
Common StockF3F25,704$5.27$30.06K46,100Direct
Filing footnotes · 4
  1. F1Restricted stock units convert to common stock on a one-for-one basis.
  2. F2Includes 4,152 and 4,152 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 30, 2025 and November 28, 2025, respectively.
  3. F3This sale was made to cover withholding taxes following the vesting of previously granted RSUs pursuant to a durable automatic sale instruction letter adopted by Mr. Tan on August 15, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Tan.
  4. F4The restricted stock units were granted on January 9, 2023 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.
Open on SEC EDGAR
Ilan GanotDirector
4
Filed Jan 6, 2026Period of report Jan 3, 20260001193125-26-004953
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 5, 2026
Common StockF21,053$5.43$5.72K17,278IndirectWife
Filing footnotes · 5
  1. F1Restricted stock units convert to common stock on a one-for-one basis.
  2. F2This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The sales do not represent a discretionary trade by Ms. Ganot.
  3. F3Represents 91,371 shares held by Mr. Ganot as an individual, and 4,042 shares held by Mr. Ganot and Annie Ganot as joint tenants with right of survivorship.
  4. F4Represents 19,394 shares held by Adam Ganot and Annie Ganot, and their successors, as the trustees for the Ilan Ganot 2017 Irrevocable Trust dated March 3, 2017.
  5. F5On January 3, 2023 (the "Grant Date"), Ms. Ganot was granted 11,975 restricted stock units, vesting in four equal installments on the anniversary of the Grant Date.
Open on SEC EDGAR
David T HowtonChief Operating Officer
4Rule 10b5-1 plan disclosed
Filed Dec 4, 2025Period of report Dec 2, 20250001193125-25-308118
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 3, 2025
Common StockF24,932$5.11$25.20K32,908Direct
Filing footnotes · 3
  1. F1Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").
  2. F2This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Mr. Howton on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Howton.
  3. F3The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.
Open on SEC EDGAR
Alexander CumboDirector · President and CEO
4Rule 10b5-1 plan disclosed
Filed Dec 4, 2025Period of report Dec 2, 20250001193125-25-308115
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 3, 2025
Common StockF310,808$5.11$55.23K81,388Direct
Filing footnotes · 4
  1. F1Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").
  2. F2Includes 2,866 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 30, 2025.
  3. F3This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Mr. Cumbo on August 18, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Cumbo.
  4. F4The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.
Open on SEC EDGAR
Jessie HanrahanChief Regulatory Officer
4Rule 10b5-1 plan disclosed
Filed Dec 4, 2025Period of report Dec 2, 20250001193125-25-308108
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 3, 2025
Common StockF24,483$5.11$22.91K26,660Direct
Filing footnotes · 3
  1. F1Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").
  2. F2This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Dr. Hanrahan on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Hanrahan.
  3. F3The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.
Open on SEC EDGAR
Paul HerzichChief Technology Officer
4Rule 10b5-1 plan disclosed
Filed Dec 4, 2025Period of report Dec 2, 20250001193125-25-308103
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 3, 2025
Common StockF32,701$5.11$13.80K26,622Direct
Filing footnotes · 4
  1. F1Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").
  2. F2Includes 1,835 and 1,861 shares of the issuer's common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 30, 2025 and November 28, 2025, respectively.
  3. F3This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Mr. Herzich on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Herzich
  4. F4The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.